Recall record at a glance
| Official record | F-0672-2017 |
|---|---|
| Category | Food Recalls |
| Classification | Class I |
| FDA record status | Terminated |
| Recalling firm | Mondelez International |
| Report date | Dec 14, 2016 |
| Recall initiation date | Oct 28, 2016 |
| Quantity | unknown |
| Location | East Hanover, NJ, United States |
Official product description
Nabisco Oreo Fudge Creme Mint Variety, Net Wt. 11.3 oz Distributed by: Mondelez Global LLC East Hanover, NJ UPC 044000026967
Why the product was recalled
Mondelez Global LLC is recalling certain Oreo Fudge Cremes (Original and mint varieties) due to milk allergen not being declared on the ingredient list.
Distribution information
Nationwide, PR, St. Croix and St. Thomas Phillipines
How to read the classification
FDA Class I indicates a situation in which there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. The classification shown here comes directly from the FDA enforcement record.
Additional record details
Recall type: Voluntary: Firm initiated. Initial notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit.
What to do next
If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.
About this record
Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.
FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.